(Total Views: 666)
Posted On: 05/04/2020 4:52:54 PM
Post# of 9124
NanoLogix Inc.
Report on technologies
To assist in the commercialization, production, and marketing of NanoLogix BNP, N-Assay, BNF, and
FlatPack technologies for use in general medical, clinical, food testing, pharmaceutical, BioDefense,
veterinarian, environmental, and other industrial areas.
Explanation of technologies:
BioNanoPore (BNP)
BioNanoFilter (BNF) (under refinement)
N-Assay Multiwell Elisa test (under development)
FlatPack unique gas-flushed vacuum packaging for BNP and a wide variety of petri plates.
Research and development of three diagnostics products for specialized and multipurpose laboratories
was first initiated by NanoLogix beginning in 2008 with the development of the BNP. The BNF followed
in 2010. The FlatPack packaging was developed independently in 2011. The N-Assay MultiWell Plate
began development in 2012 and patent application was made in 2013. The three rapid detection
technologies are an order of magnitude beyond the Petri dish methods that currently provide the
mechanism by which microorganisms and other substances and conditions are detected and analyzed in
the medical, environmental and industrial fields. Patent applications have been filed and are pending
under examination at US PTO, EPO and PCT.
The BNP patent has been granted in Japan (2013) and Russia (to be announced), and is pending in the
US, China, Brazil, India and the EU, with the EU patent expected within weeks.
BNF is pending in the US as a standalone application and via Patent Cooperation Treaty (PCT)
worldwide.
The N-Assay has been filed as a Provisional Patent application in the US, with PCT being filed.
The FlatPack packaging patent was granted in the US in April 2013 and recommended for grant by the
PCT worldwide in May. NanoLogix holds an exclusive long-term license for the packaging technology,
with the ability to sublicense to other manufacturers for use in production of products that are not within
Report on technologies
To assist in the commercialization, production, and marketing of NanoLogix BNP, N-Assay, BNF, and
FlatPack technologies for use in general medical, clinical, food testing, pharmaceutical, BioDefense,
veterinarian, environmental, and other industrial areas.
Explanation of technologies:
BioNanoPore (BNP)
BioNanoFilter (BNF) (under refinement)
N-Assay Multiwell Elisa test (under development)
FlatPack unique gas-flushed vacuum packaging for BNP and a wide variety of petri plates.
Research and development of three diagnostics products for specialized and multipurpose laboratories
was first initiated by NanoLogix beginning in 2008 with the development of the BNP. The BNF followed
in 2010. The FlatPack packaging was developed independently in 2011. The N-Assay MultiWell Plate
began development in 2012 and patent application was made in 2013. The three rapid detection
technologies are an order of magnitude beyond the Petri dish methods that currently provide the
mechanism by which microorganisms and other substances and conditions are detected and analyzed in
the medical, environmental and industrial fields. Patent applications have been filed and are pending
under examination at US PTO, EPO and PCT.
The BNP patent has been granted in Japan (2013) and Russia (to be announced), and is pending in the
US, China, Brazil, India and the EU, with the EU patent expected within weeks.
BNF is pending in the US as a standalone application and via Patent Cooperation Treaty (PCT)
worldwide.
The N-Assay has been filed as a Provisional Patent application in the US, with PCT being filed.
The FlatPack packaging patent was granted in the US in April 2013 and recommended for grant by the
PCT worldwide in May. NanoLogix holds an exclusive long-term license for the packaging technology,
with the ability to sublicense to other manufacturers for use in production of products that are not within
(0)
(0)Scroll down for more posts ▼
